Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Chief Scientist Goodman Spearheads Agency Response To Swine Flu

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS press conference marks the public debut of FDA leadership team – but in a background role.

You may also be interested in...



FDA’s Sharfstein Shows His Public Health Acumen In Capitol Hill Debut

During testimony on the flu outbreak, the agency’s acting commissioner emphasizes role of public health departments in securing access to medications.

FDA’s Sharfstein Shows His Public Health Acumen In Capitol Hill Debut

During testimony on the flu outbreak, the agency’s acting commissioner emphasizes role of public health departments in securing access to medications.

With Sebelius On The Job At HHS, Attention Moves To Health Agency Heads

Nomination hearing for FDA commissioner could be in early May; speculation in Washington on CMS chief candidates adds Geisinger exec Steele to the contenders.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel